Care Lassa Fever Test for West Africa
Alveo Technologies and the University of Texas Medical Branch are partnering to deploy a new molecular diagnostic platform for Lassa fever in Nigeria and Sierra Leone. This initiative aims to provide rapid, point-of-care testing to improve outbreak response and patient management in remote areas.
Why it matters
Improving diagnostic capabilities for viral hemorrhagic fevers is critical for public health and disease containment in underserved regions.
The molecular sensing platform will be deployed at clinical sites in Nigeria and Sierra Leone to support real-time pathogen detection. Alveo Technologies and the University of Texas Medical Branch (UTMB) have entered a partnership to develop point-of-care diagnostics for viral hemorrhagic fevers across West Africa. The initiative focuses on providing real-time pathogen detection at clinical sites in Nigeria and Sierra Leone to support the UTMB Lassa fever research program. Lassa fever affects between 100,000 and 300,000 people annually in West Africa, according to Alveo Technologies. Case fatality rates for the disease exceed 20% among hospitalized patients. Currently, the process of sending samples to distant laboratories can take weeks, creating logistical challenges for outbreak containment and patient management.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in